BridgeMD
New treatment option for Wound of Skin
Official title Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
ClinicalTrials.gov ID: NCT05462860
What this study is testing
- What it's testing
- The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Male or Female ≥18 years and ≤75 years
- Acute partial thickness burns by friction, contact, scalding from hot liquids and flame
- TBSA total ≥2 %; burn treatment region of interest: all areas with partial-thickness burns excluding face, neck, scalp, and feet
- TBSA 3rd ≤5 % (not to be included as burn treatment region of interest)
- Subject is able and willing to sign Informed Consent or via legally authorized representative
You likely can't join if
- Study Wound due to electrical, radioactive, or frostbite-related injury
- Infection of wounds in the study area at admission per Investigator or treating physician discretion
- Pregnancy/lactation
- people who are unable to follow the protocol or who are likely to be non-compliant
- Participation in an active treatment arm of a burn wound related treatment study within 90 days of Screening Visit or during the study
- Prisoners
See the full eligibility criteria
- Male or Female ≥18 years and ≤75 years
- Acute partial thickness burns by friction, contact, scalding from hot liquids and flame
- TBSA total ≥2 %; burn treatment region of interest: all areas with partial-thickness burns excluding face, neck, scalp, and feet
- TBSA 3rd ≤5 % (not to be included as burn treatment region of interest)
- Subject is able and willing to sign Informed Consent or via legally authorized representative
- Study Wound due to electrical, radioactive, or frostbite-related injury
- Infection of wounds in the study area at admission per Investigator or treating physician discretion
- Pregnancy/lactation
- people who are unable to follow the protocol or who are likely to be non-compliant
- Participation in an active treatment arm of a burn wound related treatment study within 90 days of Screening Visit or during the study
- Prisoners
- Life expectancy less than 6 months
- people who are receiving steroids, chronic anticoagulants, or immune suppressive treatment
The study team makes the final eligibility decision.
Where it's taking place
- Chapel Hill, North Carolina, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chapel Hill, North Carolina, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.